Greater Glasgow and Clyde Medicines

New Adult NHSGGC Guidelines now available on StaffNet

The NHSGGC Central Prescribing Team maintains several prescribing decision support tools for primary care such as;

MUE 09: Parkinson's Disease in Acute Care

** This bulletin supersedes MUE 01 **

Archived February 2022.

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary.

The NHSGGC guideline previously entitled ‘Anti Tumour Necrosis Factor Alpha Medications In Adult Crohn’s Disease’ has been reviewed and updated. This is now available on the Clinical Guideline Repository on Staffnet

Name change from enoxaparin Becat® to Arovi® and availability of 120mg and 150mg pre-filled syringes Key points: Enoxaparin Becat® is changing its name to Arovi®....

Dipyridamole MR 200mg is currently subject to supply disruptions, with no definitive date as to when or if the situation will be resolved. Persantin Retard® (dipyridamole 200mg MR) has been discontinued by the manufacture...

Details of the 2018-19 prescribing initiative have been sent to GP practices.  To date 89% of GP practices (210/235) have committed to undertake the following six actions. This year’s initiative focuses on: Pre...

New Adult NHSGGC Guidelines now available on StaffNet

Braltus® is the preferred brand of tiotropium inhaler in GGC.  In May 2018, the MHRA issued a warning about the risk of inhalation of the capsules if placed in the mouthpiece of the Braltus® Zonda® inhaler device. &...